Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy
- Conditions
- Atrial Fibrillation
- Registration Number
- NCT00945867
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Brief Summary
The determination of the 2D6 genotype will enable us to determine the way flecainide is metabolized by the liver. Some individuals are poor metabolizers and some individuals are extensive metabolizers of the drug. This will also determine which patients will benefit from the drug.
- Detailed Description
Pharmacogenetics is the study of genetic variations on drug metabolizing enzymes and transporters. Pharmacogenetics is one of the first clinical applications of the Human Genome Project. Pharmacogenomics is the study of the role of interindividual genomics variability on drug response, efficacy, and metabolism. It correlates the effects of the entire expressed genome to the clinical usefulness and toxicity of a drug. Pharmacogenomics has the potential to change the way patients' therapy is optimized, allowing an era of "personalized medicine" in which patients will be divided into groups based on genetic markers that treatment outcomes.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- Patients with recurrent AF
- Patients with a structurally normal heart
- Patients > 18 YO
- Patients who signed an informed consent
- Renal failure with creatinine clearance less than 40
- Elevated liver enzymes 3 times the normal range, or causing coagulation test abnormality
- Pregnant patients
- Patients treated with psychiatric agents
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method no recurrence of atrial fibrillation 3 months
- Secondary Outcome Measures
Name Time Method the dose of flecainide used 6 months
Trial Locations
- Locations (1)
Assaf Harofeh Medical Center
🇮🇱Zrifin, Israel